Drug intelligence / Profile preview

OSTA27

Development stage: Preclinical
Lead developer: Osta Therapeutics
Modality: Small Molecules

Overview

OSTA27 is a novel antibiotic candidate developed by Osta Therapeutics, designed to address the growing issue of antibiotic resistance. It utilizes the proprietary OSTA (On-Site-Target-Activated) approach, which acts as a triggerable drug delivery system activated by pathogens themselves. This mechanism allows for targeted delivery and activation of active pharmaceutical ingredients specifically at the site of infection, minimizing off-target effects and reducing the risk of resistance development. The lead indication for OSTA27 is Carbapenem-resistant Acinetobacter baumannii (CRAb) infections[1].

Beyond the preview

Go deeper on OSTA27.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OSTA27.

Explore the full profile